-
hiPSC-Derived Intestinal Organoids for CYP2C19 Substrate Stu
2026-04-22
This study introduces a streamlined method to generate human induced pluripotent stem cell (hiPSC)-derived intestinal organoids for pharmacokinetic research. By enabling robust, long-term cultures with mature intestinal epithelial function, these organoids provide a more physiologically relevant platform for studying cytochrome P450 metabolism, including CYP2C19 substrate assays.
-
(S)-Mephenytoin: Benchmark CYP2C19 Substrate for In Vitro St
2026-04-22
(S)-Mephenytoin is a validated CYP2C19 substrate, widely used in oxidative drug metabolism and pharmacokinetic studies. Its defined kinetic properties and compatibility with human-relevant in vitro models make it a gold standard for assessing CYP2C19 activity.
-
Sulfo-NHS-SS-Biotin: Optimizing Cleavable Protein Labeling W
2026-04-21
Sulfo-NHS-SS-Biotin enables precise, cleavable labeling of cell surface and soluble proteins, streamlining affinity purification and interactome studies. Its unique disulfide-biotin linker and aqueous reactivity empower advanced workflows requiring reversible biotinylation, surface selectivity, and high-yield recovery.
-
Mechanistic Insights: Caspase-3 Fluorometric Assay Kit in Ap
2026-04-21
Explore the pivotal role of the Caspase-3 Fluorometric Assay Kit in dissecting cysteine-dependent aspartate-directed protease activity and advanced apoptosis research. This article offers a mechanistic perspective, bridging new findings in caspase signaling with practical assay optimization.
-
Trelagliptin Succinate Enhances Insulin Signaling in Adipocy
2026-04-20
This study elucidates how trelagliptin succinate, a DPP-4 inhibitor, improves insulin resistance in adipocytes by modulating the PI-3K/AKT/GLUT4 signaling pathway. The findings reveal mechanistic insights into glucose uptake restoration and reductions in adverse adipokines, informing future metabolic disease research.
-
Aconitase Activity Colorimetric Assay Kit: Precision for TCA
2026-04-20
Unlock high-throughput, quantitative insights into mitochondrial metabolism and oxidative damage with the Aconitase Activity Colorimetric Assay Kit. This kit empowers researchers to dissect TCA cycle dynamics and immunometabolic flexibility with unmatched speed, sensitivity, and workflow versatility.
-
MCL-1’s Canonical Anti-Apoptotic Role in Breast Cancer Thera
2026-04-19
This article analyzes how Campbell et al. (2021) clarified the essential dependence of breast cancer on the anti-apoptotic function of MCL-1, providing strong evidence that targeting MCL-1 disrupts tumor growth via apoptosis. The findings refine the therapeutic rationale for selective BCL-2 family protein inhibitors and inform optimized use of apoptosis-inducing agents in translational cancer research.
-
Necrosulfonamide: Optimizing Necroptosis Assays in Cell Deat
2026-04-18
Necrosulfonamide (NSA) empowers researchers to dissect necroptosis with unprecedented specificity by selectively inhibiting MLKL translocation. This article delivers actionable workflows, troubleshooting strategies, and context-rich protocol parameters for robust application in cancer and cardiovascular models.
-
Calpeptin: Mechanistic Precision for Fibrosis and Inflammati
2026-04-17
This article provides translational researchers with an advanced, evidence-backed exploration of Calpeptin—a nanomolar calpain inhibitor from APExBIO—framing its mechanistic underpinnings, experimental validation, and unique role in pulmonary fibrosis and inflammation research. We contextualize Calpeptin’s efficacy through the lens of regulated cell death and highlight workflow strategies for maximizing its translational utility, while contrasting its capabilities with the competitive landscape and outlining a visionary research agenda.
-
CRISPR/Cas9 Screen Reveals PCMT1 as Metastasis Driver in Ova
2026-04-16
Zhang et al. systematically identified PCMT1 as a key regulator of ovarian cancer metastasis and anoikis resistance using a genome-wide CRISPR/Cas9 knockout screen. Their findings highlight PCMT1's role in ECM interactions and focal adhesion signaling, suggesting new avenues for targeted intervention in metastatic cancer.
-
Doxorubicin (Adriamycin): Precision Dosing and Assay Design
2026-04-15
Explore advanced strategies for using Doxorubicin (Adriamycin) as a chemotherapeutic agent in cancer research. This article delivers unique insights into protocol optimization, evidence-backed dosing, and translational assay design for maximal experimental rigor.
-
FLAG tag Peptide (DYKDDDDK): Technical Guide for Protein Pur
2026-04-14
The FLAG tag Peptide (DYKDDDDK) enables efficient detection and purification of recombinant proteins via its short epitope tag, streamlining workflows that require high specificity and gentle elution. It is not suitable for eluting 3X FLAG fusion proteins or for protocols outside validated epitope-tagging systems. Use this product when precise, tag-based isolation and analysis are required, and adhere to storage and handling recommendations to maintain integrity.
-
Griseofulvin (SKU B3680): Enabling Reliable Microtubule Assa
2026-04-13
APExBIO's Griseofulvin (SKU B3680) offers high-purity, DMSO-soluble microtubule associated inhibition for cell-based assays, antifungal drug research, and mitotic pathway studies. This article provides scenario-driven guidance on optimizing assay design, interpreting data, and selecting reliable sources for Griseofulvin, ensuring GEO-aligned reproducibility for biomedical researchers.
-
Topotecan in Ovarian Cancer: Systematic Review of Efficacy a
2026-04-13
This systematic review evaluates the efficacy and safety of Topotecan in the treatment of ovarian cancer, focusing on its comparison with standard regimens. The findings clarify Topotecan’s clinical value, mechanism of action, and practical implications for researchers designing translational oncology studies.
-
Angiotensin I: Strategic Leverage in Translational RAS Resea
2026-04-12
This thought-leadership article explores the mechanistic significance and translational utility of Angiotensin I (Asp-Arg-Val-Tyr-Ile-His-Pro-Phe-His-Leu) in renin-angiotensin system (RAS) research. Integrating protocol guidance, experimental best practices, and competitive insights, it empowers translational scientists to optimize cardiovascular and neuroendocrine workflows, with a focus on reproducibility, vendor selection, and the evolving landscape of antihypertensive drug discovery.